PODD · Q2 2026 Earnings

Cautious

Insulet Corporation

Reported August 5, 2026

30-second summary

Insulet delivered another quarter of segment-level beats — Total Omnipod +23.8% CC vs. the +21–23% guide, International a standout +32.9% CC vs. +28–30% — but management cut the FY2026 U.S. Omnipod guide by 300 bps (to +17–19% from +20–22%) and the total company guide by 100 bps despite the Q2 upside. The offsetting International raise of 400 bps and reaffirmed >25% EPS growth soften the headline, but the pattern — "updating our outlook to reflect what we're learning as we scale in type 2" — marks the first FY revenue guide cut of Ashley McEvoy's tenure and breaks the two-quarter beat-and-raise cadence that defined H1.

Headline numbers

EPS

Q2 FY2026

$1.66

+14.5% vs est.

Revenue

Q2 FY2026

$0.80B

+23.5% YoY

+1.8% vs est.

Gross margin

Q2 FY2026

70.2%

Operating margin

Q2 FY2026

16.2%

Key financials

Q2 FY2026

Metric	Q2 FY2026	Q2 FY2025	YoY	Q1 FY2026	QoQ
Revenue	$0.80B	$0.65B	+23.5%	$0.76B	+5.3%
EPS	$1.66	$1.17	+41.9%	$1.42	+16.9%
Gross margin	70.2%	69.7%	+50bps	69.5%	+70bps
Operating margin	16.2%	18.7%	-250bps	16.0%	+20bps

Guidance

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

Metric	Period	Prior guide	Actual	Δ	Result
Total Revenue Growth	Q2 FY2026	20% - 22% YoY	23.5% YoY	+1.5-3.5 pts above guide	Beat
Total Omnipod Revenue Growth	Q2 FY2026	21% - 23% YoY	23.8% YoY	+0.8-2.8 pts above guide	Beat
U.S. Omnipod Revenue Growth	Q2 FY2026	18% - 20% YoY	20.1% YoY	+0.1-2.1 pts above guide	Beat
International Omnipod Revenue Growth	Q2 FY2026	28% - 30% YoY	32.9% YoY	+2.9-4.9 pts above guide	Beat

New guidance

Metric	Period	Guide	YoY
Drug Delivery Revenue Growth	FY 2026	~(40%)	—
Total Revenue Growth	Q3 FY2026	17.5% - 19.5%	—
U.S. Omnipod Revenue Growth	Q3 FY2026	14% - 16%	—

Changes to prior guidance

Metric	Period	Prior guide	New guide	Δ	Result
Total Company Revenue Growth	FY 2026	21% - 23%	20% - 22%	-1 pt (both low and high)	Lowered
Total Omnipod Revenue Growth	FY 2026	22% - 24%	21% - 23%	-1 pt (both low and high)	Lowered
U.S. Omnipod Revenue Growth	FY 2026	20% - 22%	17% - 19%	-3 pts (both low and high)	Lowered
International Omnipod Revenue Growth	FY 2026	26% - 28%	30% - 32%	+4 pts (both low and high)	Lowered

Reaffirmed unchanged this quarter: Adjusted EPS Growth (>25%), Adjusted Operating Margin Expansion (~100 bps YoY expansion)

Segment KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
U.S. Omnipod	$0.544B	$0.453B	+20.1%
International Omnipod	$0.252B	$0.186B	+35.5%
Total Omnipod Products	$0.796B	—	+24.6%
Drug Delivery	$0.006B	$0.01B	-43.1%
International Omnipod Growth (Constant Currency)	32.9%	—	—
Total Omnipod Growth (Constant Currency)	23.8%	—	—

Other KPIs

Q2 FY2026

Segment	Q2 FY2026	Q2 FY2025	YoY
Adjusted Operating Margin	19.3%	17.8%	—
Adjusted Operating Income	$154.5 million	—	—
Adjusted Net Income Growth	+37.4%	—	—
Adjusted EPS Growth	+41.5%	—	—
Adjusted EBITDA	$199.8 million	—	—
Adjusted EBITDA Margin	24.9%	24.3%	—

Management tone

Q4 2025 (algorithmic growth + 2028 closed-loop anchor) → Q1 2026 (buffer rebuilt, competitive posture aggressive) → Q2 2026 (Type 2 scaling recalibration).

The dominant shift this quarter is the reframing of Type 2 from "flywheel" to "learning-as-we-scale." Three quarters ago Type 2 was framed as a flywheel with self-reinforcing DTC economics; two quarters ago it was reframed around primary-care call points as the durability unlock; last quarter Flavia flagged Type 2 retention would "decrease modestly"; this quarter management explicitly attaches the FY U.S. guide cut to Type 2 scaling. From the press release: "While we are updating our outlook to reflect what we're learning as we scale in type 2, our conviction in the long-term opportunity remains unchanged." This is the first quantified concession that Type 2 scaling economics are running below plan — a 300 bps FY U.S. cut is not a rounding adjustment. The "conviction unchanged" hedge is the tell that management wants the long-duration bull thesis preserved even as the near-term algebra deteriorates.

The buffer-and-beat cadence Flavia rebuilt last quarter did not survive Q2. Q1's headline was that "balanced not conservative" lasted exactly one quarter and the CFO was rebuilding the historical beat-and-raise buffer; Q2's headline is that the FY guide gets cut anyway. The Q1 raise of the total company guide (+21–23%) is now the Q2 cut back to +20–22% — a full reversal of the buffer rebuild in a single quarter. The signal is that Q1's raise was more optimistic than balanced.

International tone continues to run opposite the U.S. narrative. Last quarter management talked down International expectations while delivering the opposite; this quarter they raise the FY International guide by 400 bps — the largest single-segment FY raise of the McEvoy era. The Dash-to-Omnipod 5 conversion and new-market launches (Spain pending H2 2026) are compounding faster than the modeled deceleration.

The EPS-growth commitment is now the load-bearing beam. Revenue guide cut, gross margin under pressure, U.S. decelerating — yet FY adjusted EPS growth reaffirmed at >25% and operating margin expansion reaffirmed at ~100 bps. Management is telling investors the earnings algorithm is what matters, not the revenue mix. That works until it doesn't; the Q3 EPS print becomes the falsification test.

Answers to last quarter's watch list

Whether Q2 FY2026 Total Omnipod growth clears the +21–23% guide range. Came in at +23.8% CC, 80–280 bps above the high end — a beat, but the narrowest of the four quarters under the current framework, and the FY guide got cut 100 bps despite it. Flavia's Q1 buffer rebuild did not carry into Q2. Status: Resolved negatively

U.S. growth landing above the +18–20% guide. Came in at +20.1%, just 10 bps above the high end. This is the tightest segment beat of any print in the McEvoy era, and combined with the 300 bps FY U.S. cut, signals Type 2 contribution is not offsetting the deceleration as modeled. Status: Resolved negatively

Adjusted gross margin recovery from 71.0%. GM stepped down to 70.2% from Q1's 71.0% — the opposite of the recovery watch item. Pod-transition E&O headwinds and Middle East-driven raw materials/shipping costs from Q1 have not abated. No FY GM guide provided. Status: Resolved negatively

Capex cadence and FY2026 free cash flow tracking. Free cash flow figures for Q2 were not broken out in the press release summary; no update to the ~flat FY FCF guide was disclosed. Status: Continue monitoring

Type 2 retention disclosure framework. Management did not quantify retention rates, LTV, or cohort behavior this quarter. However, the qualitative disclosure hardened materially — the FY U.S. guide cut is explicitly attributed to "what we're learning as we scale in type 2," which is the first quantified evidence (via the guide cut) that Type 2 economics are under review. Status: Resolved negatively

International FY growth tracking toward the raised +26–28% band. Q2 delivered +32.9% CC against the +28–30% guide, and the FY International band was raised another 400 bps to +30–32%. This is the third consecutive quarter International growth exceeds the guide and forces an FY raise. Status: Resolved positively

What to watch into next quarter

Whether the Q3 FY2026 U.S. Omnipod guide of +14–16% CC holds. This is a further 400+ bps deceleration from Q2's +20.1% print, and management has now cut the FY U.S. guide once. A second U.S. cut on the Q3 call would break the "conviction unchanged" framing and force a re-underwrite of the Type 2 economics.

Adjusted EPS growth landing well above the reaffirmed >25% reference. With revenue guide cut and gross margin down 80 bps QoQ, the FY EPS commitment is now the load-bearing beam. Q3 EPS growth below ~30% would surface the mix pressure that management is currently absorbing below the line.

Adjusted gross margin bridge back above 71%. Two consecutive quarters below FY2025's 71.6% level with no FY GM guide provided leaves the run-rate ambiguous. Q3 GM below 71% would force acknowledgment that the pod-transition headwinds are structural, not transitory.

Whether the FY International +30–32% CC band is raised again. Three consecutive quarters of International beats forcing FY raises suggests the +30–32% band is still too low. A Q3 CC print of +32%+ against a +28–30% guide would tee up a fourth consecutive lift.

Any Type 2 retention or cohort quantification. Management has now acknowledged Type 2 scaling issues via a guide cut but has not disclosed retention rates, LTV, or cohort behavior. Failure to quantify on the Q3 call would leave the "conviction unchanged" narrative unsupported.

Free cash flow tracking to ~flat vs. FY2025's $377.7M. Q1 delivered $89.5M; Q2 FCF was not disclosed in the press release excerpt. With Costa Rica capex ramping and Type 2 investment increasing, an FCF guide cut on the Q3 call would compound the revenue guide cut.

Sources

Insulet Corporation Q2 FY2026 earnings press release, filed with SEC: https://www.sec.gov/Archives/edgar/data/1145197/000114519726000167/podd2026-06x30ex991.htm
Tapebrief prior-quarter coverage: PODD Q1 FY2026 brief (reported 2026-05-06); PODD Q4 FY2025 brief (reported 2026-02-18); PODD Q3 FY2025 brief (reported 2025-11-06); PODD Q2 FY2025 brief (reported 2025-08-07).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.